Literature DB >> 15990905

Relative dose intensity: improving cancer treatment and outcomes.

Cheryl Lenhart1.   

Abstract

PURPOSE/
OBJECTIVES: To determine the incidence of and reasons for chemotherapy dose delays or reductions.
DESIGN: A performance improvement initiative formed the basis for a prospective nursing research study.
SETTING: A single institution in western Pennsylvania. SAMPLE: 204 patients scheduled for nonmyeloablative chemo-therapy.
METHODS: Data collection forms were completed by RNs and evaluated by an interdisciplinary team. MAIN RESEARCH VARIABLES: Rates of nonadherence to chemotherapy schedule or dosing and associated reasons.
FINDINGS: The performance improvement initiative revealed evidence of nonadherence to chemotherapy schedule or dosing when patient-requested cancellations and physician-ordered dose delays and reductions were left unchallenged and medical and nursing staffs had limited knowledge of or interest in relative dose intensity. The ensuing nursing research study found that less than 51% and 78% of patients adhered to their schedule and dosage, respectively. Nonadherence primarily was attributed to canceled visits, suboptimal or nonuse of hematopoietic growth factors, and routine dose reductions. Subsequent educational initiatives targeting the interdisciplinary team and patients and their families focused on the importance of keeping scheduled visits and preventing versus managing pancytopenia. Adopting a telephone referral procedure and distributing a patient education sheet reduced patient cancellations by 50%. Various reasons for dose delays and reductions have surfaced, many of which are modifiable with educational efforts.
CONCLUSIONS: A knowledge deficit was found among patients and healthcare providers regarding the importance of adhering to chemo-therapy orders. IMPLICATIONS FOR NURSING: Evaluating patterns of chemotherapy administration and educating patients, nurses, and physicians will have an impact on relative dose intensity, potentially improving treatment outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990905     DOI: 10.1188/05.ONF.757-764

Source DB:  PubMed          Journal:  Oncol Nurs Forum        ISSN: 0190-535X            Impact factor:   2.172


  5 in total

1.  Novel Methods for Reporting of Exercise Dose and Adherence: An Exploratory Analysis.

Authors:  Tormod S Nilsen; Jessica M Scott; Meghan Michalski; Catherine Capaci; Samantha Thomas; James E Herndon; John Sasso; Neil D Eves; Lee W Jones
Journal:  Med Sci Sports Exerc       Date:  2018-06       Impact factor: 5.411

2.  Dose intensity in early-stage breast cancer: a community practice experience.

Authors:  Robert L Bretzel; Ralph Cameron; Marc Gustas; Maria A Garcia; Heather K Hoffman; Rosalind Malhotra; Karen Miller; Janine Prime; Anne Favret
Journal:  J Oncol Pract       Date:  2009-11       Impact factor: 3.840

3.  Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting.

Authors:  Ilanit Shalom-Sharabi; Ofer Lavie; Noah Samuels; Lital Keinan-Boker; Efraim Lev; Eran Ben-Arye
Journal:  J Cancer Res Clin Oncol       Date:  2017-08-20       Impact factor: 4.553

4.  Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer.

Authors:  Heejung Ban; Kyu-Sik Kim; In-Jae Oh; Seong-Hoon Yoon; Boram Lee; Jinyeong Yu; Sunmin Kim; Ho-Sung Lee; Hong-Joon Shin; Cheol-Kyu Park; Yong-Soo Kwon; Yu-Il Kim; Sung-Chul Lim; Young-Chul Kim
Journal:  Thorac Cancer       Date:  2014-10-23       Impact factor: 3.500

5.  Prognostic factors in patients after definitive chemoradiation using involved-field radiotherapy for esophageal cancer in a phase II study.

Authors:  Hideomi Yamashita; Ryousuke Takenaka; Kae Okuma; Kuni Ootomo; Keiichi Nakagawa
Journal:  Thorac Cancer       Date:  2016-06-02       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.